Spectrum (SPPI -3.1%) is at odds with Danish partner TopoTarget over the results of a Phase II...


Spectrum (SPPI -3.1%) is at odds with Danish partner TopoTarget over the results of a Phase II trial for their lymphoma drug belinostat. TopoTarget says the primary endpoint has been met, as the tumors in at least 20% of patients shrank. However, Spectrum is far more cautious, describing the results as "preliminary" and saying that the full outcome won't be known until all the data is analyzed. (PR)

Comments (2)
  • mitrado
    , contributor
    Comments (2032) | Send Message
     
    Another bearish article by the Feuerstein Troll? Doesn't bother me.
    It's when he's bullish one should be careful.

     

    If SPPI reaches 11.5, I'm buying some to sell at 12.5, while I wait for the roller-coaster to end. (I have a few SPPI shares that I won't sell below $17.)
    24 Sep 2012, 11:51 AM Reply Like
  • Factzplz
    , contributor
    Comments (291) | Send Message
     
    Another Seeking Alpha whore headline --

     

    "...at odds..." ??? Perhaps you should read before you write, or perhaps, read the Ten Commandments (assuming you are Christian) and tell the truth.

     

    UPOD - Under Promise Over Deliver

     

    Given the way the shorts (and Seeking Alpha) jump on every bit of news, personnally I am glad for the "news embargo" until the trial is fully completed. After the lies that Fusilev was discounted 50%, versus statements last week that there was a 10% price INCREASE, profits should continue to be exceptional.

     

    Bought more SPPI today.
    24 Sep 2012, 02:09 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs